Nishijima Yoshinori, Cao Sheng, Chabowski Dawid S, Korishettar Ankush, Ge Alyce, Zheng Xiaodong, Sparapani Rodney, Gutterman David D, Zhang David X
From the Department of Medicine (Y.N., S.C., D.S.C., A.K., A.G., X.Z., D.D.G., D.X.Z.), Cardiovascular Center (Y.N., S.C., D.S.C., A.K., A.G., X.Z., D.D.G., D.X.Z.), Department of Pharmacology and Toxicology (D.S.C., A.K.), Division of Biostatistics (R.S.), Medical College of Wisconsin, and Zablocki Veterans Affairs Medical Center (D.D.G.), Milwaukee, WI.
Circ Res. 2017 Feb 17;120(4):658-669. doi: 10.1161/CIRCRESAHA.116.309491. Epub 2016 Nov 21.
Hydrogen peroxide (HO) regulates vascular tone in the human microcirculation under physiological and pathophysiological conditions. It dilates arterioles by activating large-conductance Ca-activated K channels in subjects with coronary artery disease (CAD), but its mechanisms of action in subjects without CAD (non-CAD) when compared with those with CAD remain unknown.
We hypothesize that HO-elicited dilation involves different K channels in non-CAD versus CAD, resulting in an altered capacity for vasodilation during disease.
HO induced endothelium-independent vasodilation in non-CAD adipose arterioles, which was reduced by paxilline, a large-conductance Ca-activated K channel blocker, and by 4-aminopyridine, a voltage-gated K (K) channel blocker. Assays of mRNA transcripts, protein expression, and subcellular localization revealed that K1.5 is the major K1 channel expressed in vascular smooth muscle cells and is abundantly localized on the plasma membrane. The selective K1.5 blocker diphenylphosphine oxide-1 and the K1.3/1.5 blocker 5-(4-phenylbutoxy)psoralen reduced HO-elicited dilation to a similar extent as 4-aminopyridine, but the selective K1.3 blocker phenoxyalkoxypsoralen-1 was without effect. In arterioles from CAD subjects, HO-induced dilation was significantly reduced, and this dilation was inhibited by paxilline but not by 4-aminopyridine, diphenylphosphine oxide-1, or 5-(4-phenylbutoxy)psoralen. K1.5 cell membrane localization and diphenylphosphine oxide-1-sensitive K currents were markedly reduced in isolated vascular smooth muscle cells from CAD arterioles, although mRNA or total cellular protein expression was largely unchanged.
In human arterioles, HO-induced dilation is impaired in CAD, which is associated with a transition from a combined large-conductance Ca-activated K- and K (K1.5)-mediated vasodilation toward a large-conductance Ca-activated K-predominant mechanism of dilation. Loss of K1.5 vasomotor function may play an important role in microvascular dysfunction in CAD or other vascular diseases.
过氧化氢(HO)在生理和病理生理条件下调节人体微循环中的血管张力。在冠状动脉疾病(CAD)患者中,它通过激活大电导钙激活钾通道使小动脉扩张,但其在无CAD(非CAD)患者中与CAD患者相比的作用机制仍不清楚。
我们假设HO引起的扩张在非CAD和CAD中涉及不同的钾通道,导致疾病期间血管舒张能力改变。
HO在非CAD脂肪小动脉中诱导非内皮依赖性血管舒张,大电导钙激活钾通道阻滞剂紫杉醇和电压门控钾(K)通道阻滞剂4-氨基吡啶可使其降低。mRNA转录本、蛋白质表达和亚细胞定位分析表明,K1.5是血管平滑肌细胞中表达的主要K1通道,大量定位于质膜上。选择性K1.5阻滞剂二苯基氧化膦-1和K1.3/1.5阻滞剂5-(4-苯基丁氧基)补骨脂素将HO引起的扩张降低到与4-氨基吡啶相似的程度,但选择性K1.3阻滞剂苯氧基烷氧基补骨脂素-1无效。在CAD患者的小动脉中,HO诱导的扩张显著降低,这种扩张被紫杉醇抑制,但不被4-氨基吡啶、二苯基氧化膦-1或5-(4-苯基丁氧基)补骨脂素抑制。在CAD小动脉分离的血管平滑肌细胞中,K1.5细胞膜定位和二苯基氧化膦-1敏感的钾电流明显降低,尽管mRNA或总细胞蛋白表达基本不变。
在人类小动脉中,HO诱导的扩张在CAD中受损,这与从大电导钙激活钾通道和K(K1.5)介导的联合血管舒张向大电导钙激活钾通道为主的舒张机制转变有关。K1.5血管运动功能丧失可能在CAD或其他血管疾病的微血管功能障碍中起重要作用。